Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Primary Outcome
研究概览
简要总结
This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.
Patients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.
详细描述
This investigator-initiated randomised, single-blind, placebo-controlled cross-over study aims to better understand tubular electrolyte handling of divalent ions in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.
After randomization, at week 0, participants collect 24-hour urine sample and a patient visit to assess vitals and blood tests takes place. After this visit, period 1 starts with a 2-week treatment of either Empagliflozin 10mg or Placebo.
At week 2, the second 24-hour-urine sample and 2. patient visit and blood test take place. After this visit, wash-out period for 2 weeks starts where no study drug will be administered At week 4, the period 2, the crossover-period starts for an additional 2 weeks. At week 6; a final and third 24-hour urine sample, clinical visit and blood test takes place.
At week 3 & 7, a phone consultation will assess safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- Patients 18-75 years old with ADPKD, defined according to international diagnostic and classification criteria14, treated at Cantonal Hospital Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of baseline treatment with the vasopressin receptor antagonist Tolvaptan
- •Informed consent as documented by signature
排除标准
- •- renal replacement therapy or kidney allograft recipient
- •chronic kidney disease CKD KDIGO Stage G4 (eGFR under 30ml/min/1.73m2)
- •patients younger 18 years of age
- •Diabetes mellitus type 1
- •recurrent urinary tract infections (UTI) defined as more than 3 infections requiring antibiotic treatment or over 1 requiring hospitalization/year.
- •Patients with uncontrolled hypertension (defined as ambulatory systolic BP over 180mmHg), liver cirrhosis (Child Pugh B and C)
- •Patients not able or not willing to stop the following medications during the study period of participation in the trial:
- •Thiazide diuretics
- •Carbonic anhydrase inhibitors
- •Sodium bicarbonate
- •1, 25 (OH) vitamin D (calcitriol)
- •Bisphosphonate, denosumab, teriparatide
- •Pregnant or lactating women
- •Known allergy to study drug
- •Inability to understand and follow the protocol
研究组 & 干预措施
Intervention
Empagliflozin 10mg
干预措施: Empagliflozin (Drug)
Control
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Primary Outcome
时间窗: After a two week intervention
\- Calcium, phosphate, magnesium excretion
次要结局
- Secondary Outcome(After a two week intervention)
研究者
Patrick Hofmann
Principal Investigator
Cantonal Hospital Graubuenden